NCI Discovery May Be Used Toward Cancer Vaccine Development – On June 8 the National Cancer Institute (NCI) announced that it had determined the structure of thin fibers that are commonly found on the surface of a type of E. coli bacteria responsible for traveler’s diarrhea. The researchers, who work in NCI’s Center for Cancer Research, employed atomic resolution technology to determine how the fibers assemble upon exit from the cells through a pore on the bacterial surface. Knowledge of …

Description:

Kyprolis, which is a second-generation proteasome inhibitor, selectively targets the …

On May 18 the Multiple Myeloma Research Foundation (MMRF) announced plans to collaborate with the Broad Institute of MIT and Harvard on a genetic analysis of multiple myeloma tumors. The MMRF, which is the financial sponsor of the project, will provide the patient samples for genomic sequencing of individual patient tumors. The data collected during the study will later be made available for the public domain.

"Through our work together on this critical pilot project in whole cancer genome sequencing, …

On May 12 the National Cancer Institute published an updated report on its ongoing study of industrial workers with high formaldehyde exposure. The findings indicate a possible link between high formaldehyde exposure and increased risk of cancers of the blood and lymphatic system, most notably Hodgkin’s lymphoma, multiple myeloma, and myeloid leukemia.

"The overall patterns of risk seen in this extended follow-up of industrial workers, while not definitive, are consistent with a causal association between formaldehyde exposure and cancers of …

OICR Announces $2.25 Million In Funding Toward Cancer Research — On April 22, the Ontario Institute for Cancer Research (OICR) announced that it would invest $2.25 million in five promising early-stage cancer technologies. One recipient of the award, Dr. Aaron Schimmer of the Princess Margaret Hospital Cancer Program in Toronto, has identified a proteasome inhibitor (5AHQ) that may be used to stop development of multiple myeloma tumors. Because 5AHQ operates using a different mechanism from another commonly used proteasome inhibitor, …

The Road To Discovery: Emerging Therapies In Blood Cancers — The Leukemia & Lymphoma Society (LLS) will host a free patient education program on April 30 from 5:30 p.m. to 7:30 p.m. at The White Inn in Fredonia, NY. The program will discuss how new drugs are discovered, researched, and approved for treatment; recent and ongoing advances in the treatment of blood cancers; and participation in clinical trials as a possible treatment option. Pre-registration for this event is required …

Boston Marathon — Registration for the 2009 Boston Marathon on April 20 has already closed, but those who are interested in racing or sponsoring entries for multiple myeloma research may attain a charity entry through the MMRF or the IMF. The MMRF requires an online application and a fundraising minimum of $5000. The IMF is sponsoring the Marathon for Mom, which is asking for donations in honor of Gail Pollard, a patient who was recently diagnosed with multiple …